In a previous editorial, one of us (W.T.C.) tweet-styled “Things I do not like” ranging from what is wrong with Positive and Negative Syndrome Scale (PANSS) total scores, what to do with first degree relatives, stigma, P-values and a brief tweet on ethics of antipsychotic (AP) clinical trials.1 Two of us now provide here a new list of things we do not like related to how our field conceptualizes AP medications and conducts research to evaluate their efficacy. This time a more on the ethics of placebo-controlled AP trials.